PHARMA MAR, S.A. «...1617181920...» Page 20 out of 27 01/03/2021 09:22 PHARMA MAR, S.A. On business and financial situation The Company announces the signature of a new license agreement with Adium to commercialize Zepzelca® (lurbinectedin) in Latin America. Register number: 7654 26/02/2021 18:00 PHARMA MAR, S.A. Annual report on directors´ remunerations La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del Ejercicio 2020 Register number: 7624 26/02/2021 17:58 PHARMA MAR, S.A. Annual corporate governance report La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2020 Register number: 7623 26/02/2021 17:52 PHARMA MAR, S.A. Other relevant information - On business and financial situation The Company reports draw up of the Annual Financial Statements 2020, a proposal for a dividend, resolution to convene a General Shareholders’ Meeting, and a conference call with analysts and investors. Register number: 7621 26/02/2021 17:41 PHARMA MAR, S.A. On business and financial situation The Company sends press release regarding year 2020 results together with financial report. Register number: 7616 26/02/2021 17:36 PHARMA MAR, S.A. Half-yearly financial reports and audit reports/limited audit review La sociedad remite información financiera del segundo semestre de 2020 Register number: 7615 17/02/2021 10:55 PHARMA MAR, S.A. On business and financial situation The Company announces that it has obtained Medicines and Healthcare products Regulatory Agency (MHRA) approval for UK patients to participate in the Phase III NEPTUNO clinical trial. Register number: 7133 01/02/2021 08:25 PHARMA MAR, S.A. On business and financial situation The Company sends a press release regarding the presentation of new data on Zepzelca® (lurbinectedin) in combination with irinotecan during the IASLC 2020 World Lung Cancer Conference. Register number: 6867 26/01/2021 07:41 PHARMA MAR, S.A. Other relevant information The Company reports that the publication titled “Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A” has been published in Science. Register number: 6765 08/01/2021 09:51 PHARMA MAR, S.A. Board of Directors Regulations La sociedad remite el reglamento del Consejo de Administración Register number: 6516 Page 20 out of 27 «...1617181920...»
